Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer
Authors:
- Walter JentzenWJWalter Jentzen
- Elke SchneiderESElke Schneider
- Lutz FreudenbergLFLutz Freudenberg
- Ernst G EisingEEErnst G Eising
- Rainer GörgesRGRainer Görges
- Stefan P MüllerSMStefan P Müller
- Wofgang BrandauWBWofgang Brandau
- Andreas BockischABAndreas Bockisch
- 1 August 2006
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 27 (8) , 669-676
Abstract
To estimate the individual absorbed dose to the parotid and submandibular salivary glands in radioiodine therapy and its dependence from the previous cumulative therapy. Fifty-five patients with differentiated thyroid carcinoma after thyroidectomy received 1-21 GBq (131)I using single activities of 1-6 GBq. The patients were stratified according to the cumulative activities into low-activity (1-2 GBq), middle-activity (3-7 GBq), and high-activity groups (9-21 GBq). The time-activity curves over the respective salivary glands were derived from multiple static calibrated images measured for each patient up to 48 h after ingestion of the radioiodine therapy capsule with a gamma camera. Manually drawn regions of interests were used to determine the background activities and the activities arising from the salivary glands. The gland volumes were determined by ultrasonography using appropriate volume models. The median absorbed dose per administered activity of each single parotid and submandibular gland was about 0.15 Gy.GBq (range, 0.1-0.3 Gy.GBq(-1)) and 0.48 Gy.GBq(-1) (range, 0.2-1.2 Gy.GBq(-1)), respectively. The maximum uptake of both gland types was significantly lower for the high-activity than for the low-activity groups and correlated with the mean cumulative administered activity of the activity groups. The iodine uptake of salivary glands is significantly reduced, whereas the absorbed dose per administered (131)I activity was not significantly decreased during the course of therapy. Comparing the well-known dose-effect relationships in external radiation therapy, the absorbed dose per administered (131)I activity is too low to induce comparable radiation damage, suggesting an inhomogeneous distribution of (131)I in human salivary glands.Keywords
This publication has 15 references indexed in Scilit:
- Scintigraphic Evaluation of Salivary Gland Dysfunction in Patients with Thyroid Cancer After Radioiodine TreatmentClinical Nuclear Medicine, 2002
- Die quantitative Sialoszintigraphie -eine sinnvolle Untersuchung im Vorfeld und in der Nachsorge der RadiojodtherapieNuklearmedizin-Nuclear Medicine, 1997
- Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodineNuclear Medicine Communications, 1996
- Value of quantitative salivary gland scintigraphy in the early stage of Sjörgenʼs syndromeNuclear Medicine Communications, 1995
- Major salivary gland function in patients with radiation-induced xerostomia: Flow rates and sialochemistryInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1993
- Parotid gland function during and following radiotherapy of malignancies in the head and neckEuropean Journal of Cancer, 1992
- Funktionsszintigraphie der Speicheldrüsen nach hochdosierter Radiojodtherapie*RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, 1976
- Radiation Sialitis following Radioiodine TherapyBritish Journal of Radiology, 1957
- The Role of Radioiodine in the Treatment of Carcinoma of the ThyroidBritish Journal of Radiology, 1956
- Autoradiographic Localization of Iodine-131 in the Salivary Glands of the HamsterNature, 1955